• Alamar Biosciences partnered with Nightingale Health to launch a UK Biobank study of neurodegenerative disease biomarkers in 80,000 blood samples.
• Nightingale's laboratories will use Alamar's NULISA platform to measure hundreds of circulating protein biomarkers, with completion expected by the end of 2027.
• The Michael J. Fox Foundation, Alzheimer's Research UK and LifeArc are funding the study.
• The full dataset will become available to approved researchers worldwide to support earlier detection and treatment research.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alamar Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611021905PRIMZONEFULLFEED9868722) on November 03, 2026, and is solely responsible for the information contained therein.